MX2021010467A - Biomarcadores para dolencias articulares y usos de estos. - Google Patents

Biomarcadores para dolencias articulares y usos de estos.

Info

Publication number
MX2021010467A
MX2021010467A MX2021010467A MX2021010467A MX2021010467A MX 2021010467 A MX2021010467 A MX 2021010467A MX 2021010467 A MX2021010467 A MX 2021010467A MX 2021010467 A MX2021010467 A MX 2021010467A MX 2021010467 A MX2021010467 A MX 2021010467A
Authority
MX
Mexico
Prior art keywords
biomarkers
joint
ailments
joint ailments
monitor
Prior art date
Application number
MX2021010467A
Other languages
English (en)
Inventor
Mercedes Vazquez-Anon
Karen Wedekind
Juxing Chen
Original Assignee
Novus Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novus Int Inc filed Critical Novus Int Inc
Publication of MX2021010467A publication Critical patent/MX2021010467A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a biomarcadores que están asociados con trastornos articulares, y métodos para usar los biomarcadores diagnosticar dolencias articulares, monitorear el avance de las dolencias articulares, determinar cuándo se indican los tratamientos y monitorear la eficacia del tratamiento. También se proporcionan métodos para tratar dolencias articulares, que comprenden administrar minerales traza quelados a animales diagnosticados con o predispuestos a tener dolencias articulares.
MX2021010467A 2019-03-12 2020-03-12 Biomarcadores para dolencias articulares y usos de estos. MX2021010467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817121P 2019-03-12 2019-03-12
PCT/US2020/022389 WO2020186057A1 (en) 2019-03-12 2020-03-12 Biomarkers for joint ailments and uses thereof

Publications (1)

Publication Number Publication Date
MX2021010467A true MX2021010467A (es) 2021-10-01

Family

ID=72424859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010467A MX2021010467A (es) 2019-03-12 2020-03-12 Biomarcadores para dolencias articulares y usos de estos.

Country Status (7)

Country Link
US (2) US11376279B2 (es)
EP (1) EP3938044A4 (es)
CN (1) CN113660982A (es)
AU (1) AU2020237509A1 (es)
BR (1) BR112021014054A2 (es)
MX (1) MX2021010467A (es)
WO (1) WO2020186057A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113660982A (zh) * 2019-03-12 2021-11-16 诺华丝国际股份有限公司 用于关节小病的生物标志物和其用途
WO2023060131A1 (en) * 2021-10-05 2023-04-13 Novus International, Inc. Methods for predicting and treating lameness
WO2023092192A1 (en) * 2021-11-25 2023-06-01 TelemedVet Pty Ltd Method for detecting equine bone injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497435A1 (en) * 2002-09-06 2004-03-18 Agristudio S.R.L. Use of metal chelates in human or animal feeding
US8968791B2 (en) * 2007-06-06 2015-03-03 Novus International, Inc. Dietary supplements for promotion of growth, repair, and maintenance of bone and joints
EP2171449A2 (en) * 2007-06-20 2010-04-07 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US20140142861A1 (en) * 2010-11-06 2014-05-22 Oklahoma Medical Research Foundation Biomarkers For Predicting Progressive Joint Damage
CA2824380A1 (en) * 2011-01-10 2012-07-19 Esm Technologies, Llc Dietary supplements for promotion of growth, repair, and maintenance of bone and joints
WO2015009754A2 (en) * 2013-07-15 2015-01-22 Svoboda Steven J Methods and apparatus for assessment of risk for joint injury
CN113660982A (zh) 2019-03-12 2021-11-16 诺华丝国际股份有限公司 用于关节小病的生物标志物和其用途

Also Published As

Publication number Publication date
US20220296640A1 (en) 2022-09-22
EP3938044A4 (en) 2023-04-12
WO2020186057A1 (en) 2020-09-17
BR112021014054A2 (pt) 2021-09-21
AU2020237509A1 (en) 2021-08-05
US20200289555A1 (en) 2020-09-17
US11376279B2 (en) 2022-07-05
EP3938044A1 (en) 2022-01-19
CN113660982A (zh) 2021-11-16

Similar Documents

Publication Publication Date Title
MX2021010467A (es) Biomarcadores para dolencias articulares y usos de estos.
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
PH12017500032A1 (en) Improved a� protofibril binding antibodies
MX2022001008A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2021003006A (es) Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
EA202090513A1 (ru) Агенты, модулирующие функции бета-катенина, и связанные способы
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.